{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.137G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "137"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "46"
          },
          "Description in input context": "c.137G>A (p.E46K)"
        },
        {
          "HGVS": "NM_001126112.3:c.137G>C",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "C",
            "position": "137"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "A",
            "position": "46"
          },
          "Description in input context": "c.137G>C (p.E46A)"
        },
        {
          "HGVS": "NM_001126112.3:c.248G>A",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "A",
            "position": "248"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "K",
            "position": "83"
          },
          "Description in input context": "c.248G>A (p.E83K)"
        },
        {
          "HGVS": "NM_001126112.3:c.248G>C",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "G",
            "alt": "C",
            "position": "248"
          },
          "Protein Change": {
            "ref": "E",
            "alt": "A",
            "position": "83"
          },
          "Description in input context": "c.248G>C (p.E83A)"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0002041"
  },
  "Experiment Method": [
    {
      "Assay Method": "Fibril formation assay",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293",
        "Description": "Recombinant α-synuclein variants were expressed in HEK293 cells."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.137G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Increased fibril formation",
          "Result Description": "E46K mutation increased fibril formation compared to wild-type."
        },
        {
          "Variant": "NM_001126112.3:c.137G>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Altered fibril morphology",
          "Result Description": "E46A mutation resulted in distinct fibril ultrastructure."
        },
        {
          "Variant": "NM_001126112.3:c.248G>A",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Enhanced aggregation propensity",
          "Result Description": "E83K mutation showed higher aggregation rates."
        },
        {
          "Variant": "NM_001126112.3:c.248G>C",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Reduced solubility",
          "Result Description": "E83A mutation caused decreased protein solubility."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not specified in the literature."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not specified in the literature."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type α-synuclein was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector transfection served as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": 0
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": 0
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Fibril formation rate < 20% of wild-type",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Fibril formation rate > 50% of wild-type",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}